SCI FALECHE SAS

About SCI FALECHE SAS

SCI FALECHE SAS is primarily identified in Predilife corporate filings as a governance and asset-holding vehicle linked to Stéphane Ragusa, the key figure behind the company. Within Predilife, Stéphane Ragusa serves as Chairman and Chief Executive Officer and is the company’s founder. His outside-group mandates include acting as manager of SCI Faleche et Colombier since 2022. This role fits into a broader career as an entrepreneur and executive focused on applied science, data, and healthcare innovation. Ragusa founded Predilife in 2004, positioning it as a French pioneer in predictive medicine. The original idea reportedly emerged from his academic and scientific background, while he was teaching mathematics applied to medicine and working at the Gustave Roussy cancer center, where he began thinking about whether diseases could be anticipated earlier to improve prevention. He holds a doctorate in biology and graduated from École Polytechnique, giving him a distinctive profile at the intersection of statistics, biology, artificial intelligence, and medical prevention. Under his leadership, Predilife spent more than a decade in research and development before obtaining medical device certification and launching predictive health check-ups, first focused on breast cancer and later expanded to multiple conditions. The company then built a B2B offering for employers, insurers, and healthcare professionals, centered on personalized prevention and digital delivery. Since 2018, Predilife has been listed on Euronext Growth, increasing the importance of governance discipline, financial reporting, and strategic execution. Ragusa’s role is not limited to operational leadership. He also holds a meaningful equity stake in Predilife, both directly and indirectly through ACM Participations, making him an executive-shareholder with a strong alignment to the company’s long-term interests. His profile combines scientific credibility, entrepreneurial vision, and capital commitment. The reference to SCI Faleche et Colombier in his external mandates also reflects the kind of family or patrimonial holding structure often seen among French listed-company leaders. Overall, his track record reflects long-term entrepreneurial governance built on medical innovation, value creation, and international development.